Significance of Lauren Classification in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany.

Lauren histotype gastric/gastroesophageal cancer perioperative chemotherapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
14 Jan 2021
Historique:
received: 01 12 2020
revised: 30 12 2020
accepted: 31 12 2020
entrez: 20 1 2021
pubmed: 21 1 2021
medline: 21 1 2021
Statut: epublish

Résumé

the purpose of this analysis was to analyze the outcomes of multimodal treatment that are related to Lauren histotypes in gastro-esophageal cancer (GEC). patients with GEC between 1986 and 2013 were analyzed. Uni- and multivariate regression analysis were performed to identify predictors for overall survival. Lauren histotype stratified overall survival (OS)-rates were analyzed by the Kaplan-Meier method. Further, propensity score matching (PSM) was performed to balance for confounders. 1290 patients were analyzed. After PSM, the median survival was 32 months for patients undergoing primary surgery (PS) and 43 months for patients undergoing neoadjuvant chemotherapy (nCTx) ahead of surgery. For intestinal types, median survival time was 34 months (PS) vs. 52 months (nCTx+surgery) the Lauren histotype might be predictive for survival outcome in GEC-patients after neoadjuvant/perioperative chemotherapy.

Sections du résumé

BACKGROUND BACKGROUND
the purpose of this analysis was to analyze the outcomes of multimodal treatment that are related to Lauren histotypes in gastro-esophageal cancer (GEC).
METHODS METHODS
patients with GEC between 1986 and 2013 were analyzed. Uni- and multivariate regression analysis were performed to identify predictors for overall survival. Lauren histotype stratified overall survival (OS)-rates were analyzed by the Kaplan-Meier method. Further, propensity score matching (PSM) was performed to balance for confounders.
RESULTS RESULTS
1290 patients were analyzed. After PSM, the median survival was 32 months for patients undergoing primary surgery (PS) and 43 months for patients undergoing neoadjuvant chemotherapy (nCTx) ahead of surgery. For intestinal types, median survival time was 34 months (PS) vs. 52 months (nCTx+surgery)
CONCLUSION CONCLUSIONS
the Lauren histotype might be predictive for survival outcome in GEC-patients after neoadjuvant/perioperative chemotherapy.

Identifiants

pubmed: 33466779
pii: cancers13020290
doi: 10.3390/cancers13020290
pmc: PMC7830383
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

PLoS One. 2017 Sep 18;12(9):e0183891
pubmed: 28922362
Cancer. 2003 Oct 1;98(7):1521-30
pubmed: 14508841
Eur J Cancer. 2017 May;76:27-35
pubmed: 28262585
Acta Pathol Microbiol Scand. 1965;64:31-49
pubmed: 14320675
J Clin Oncol. 2010 Dec 10;28(35):5210-8
pubmed: 21060024
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
J Clin Oncol. 2011 May 1;29(13):1715-21
pubmed: 21444866
Ann Surg. 2011 Nov;254(5):684-93; discussion 693
pubmed: 22005144
Z Gastroenterol. 2011 Apr;49(4):461-531
pubmed: 21476183
BMC Cancer. 2013 Jun 10;13:281
pubmed: 23758655
J Clin Oncol. 2006 Sep 10;24(26):4347-55
pubmed: 16963732
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
J Clin Oncol. 2013 Jun 1;31(16):2059-60
pubmed: 23610107
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Gastric Cancer. 2017 Mar;20(2):217-225
pubmed: 26897166
Gastric Cancer. 2017 Jan;20(1):1-19
pubmed: 27342689
J Surg Oncol. 2013 Mar;107(3):230-6
pubmed: 23129495
Ann Surg. 2018 Jan;267(1):105-113
pubmed: 27759618
J Clin Oncol. 2019 Dec 10;37(35):3392-3400
pubmed: 31513484
Onkologie. 2011;34(12):682-6
pubmed: 22156447
Int J Cancer. 2019 Dec 15;145(12):3218-3230
pubmed: 30771224
Eur J Cancer. 2013 Oct;49(15):3149-58
pubmed: 23800671
Gastric Cancer. 2019 Jan;22(1):1-9
pubmed: 30167905
J Gastrointest Oncol. 2017 Feb;8(1):148-163
pubmed: 28280619
Br J Cancer. 2017 Sep 5;117(6):775-782
pubmed: 28765618
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686

Auteurs

Rebekka Schirren (R)

Department of Surgery, TUM School of Medicine, Technical University Munich, 81675 Munich, Germany.

Alexander Novotny (A)

Department of Surgery, TUM School of Medicine, Technical University Munich, 81675 Munich, Germany.

Christian Oesterlin (C)

Department of Surgery, TUM School of Medicine, Technical University Munich, 81675 Munich, Germany.

Julia Slotta-Huspenina (J)

Institute of Pathology, TUM School of Medicine, Technical University Munich, 81675 Munich, Germany.

Helmut Friess (H)

Department of Surgery, TUM School of Medicine, Technical University Munich, 81675 Munich, Germany.

Daniel Reim (D)

Department of Surgery, TUM School of Medicine, Technical University Munich, 81675 Munich, Germany.

Classifications MeSH